[fr] La dépression est un problème majeur de santé publique. selon l’organisation Mondiale de la santé (oMs), elle est actuellement la deuxième cause de handicap dans les pays développés. La dépression majeure est aussi une des formes de psychopathologie les plus fréquentes. Environ un homme sur six et une femme sur quatre sont susceptibles d’être touchés, au cours de leur vie, par la dépression. dans le traitement de la dépression, l’objectif majeur est d’atteindre la rémission complète et de prévenir les récidives. Malheureusement, cet objectif de guérison reste difficile d’accès en pratique clinique. En effet, le taux de rémission complète obtenu dans les études cliniques ou les études naturalistes est généralement assez bas, dépassant rarement les 35%. Heureusement, différentes stratégies thérapeutiques existent pour augmenter les chances de rémission complète. Des options thérapeutiques comme le changement d’antidépresseur, la potentialisation et l’association d’antidépresseurs peuvent se révéler très efficaces. Certaines approches sont manifestement plus performantes que d’autres, mais le choix se fait souvent sur base de l’expérience du clinicien. Les données scientifiques restent en effet assez limitées dans le domaine du traitement de la dépression résistante. A côté des options pharmacologiques, la psychothérapie ainsi que les techniques de stimulation cérébrale ont également fait preuve de leur efficacité.
Disciplines :
Psychiatry
Author, co-author :
PITCHOT, William ; Centre Hospitalier Universitaire de Liège - CHU > Psychiatrie et psychologie médicale
Scantamburlo, Gabrielle ; Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale
Pinto, Emmanuel ; Université de Liège - ULiège > Département des sciences cliniques
Ansseau, Marc ; Département des sciences cliniques > Psychiatrie et psychologie médicale
Language :
French
Title :
Guérir la dépression : une question d'objectif et de détermination.
Publication date :
2010
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
World Health Organisation. World Health Report 2001 Mental health : new understanding, new hope. Geneva : World Health Organization, 2001.
Kessler RC, McGonagle KA, Zhao s, et al. - Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry, 1994, 51, 8-19.
Pitchot W, Dierick M, D'Haenen H. - Troubles affectifs. In Dierick M, Ansseau M, D'Haenen H, Peuskens J, Linkowski P (Eds), Manuel de Psychopharmacologie. Gent Academia Press, 2003, 169-229.
Keller M. - Remission versus response : the new gold standard of antidepressant care. J Clin Psychiatry, 2004, 65, 53-59.
Rush AJ, Trivedi MH, Wisniewski SR, et al. - Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med, 2006, 354, 1231-1242.
Souery D, Oswald P, Massat I, et al. - Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry, 2007, 68, 1062-1070.
Bollen J, Constant E, Domken MA, et al. - Striving for remission in depression through bette rand broader symptom control. Acta Psychiatrica Belgica, 2006, 106, 121-133.
Ferrier IN. - Characterizing the ideal antidepresnt therapy to achieve remission. J Clin Psychiatry, 2001, 62, 10-15.
Souery D, Amsterdam J, de Montigny C, et al. - Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol, 1999, 9, 83-91. (Pubitemid 29073687)
Thase ME, Rush AJ. - When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry, 1997, 58, 23-29.
Petersen T, Papakostas GI, Posternak MA, et al. - Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharcol, 2005, 25, 336-341. (Pubitemid 41060253)
Demyttenaere K, Adelin A, Patrick M, et al. - Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol, 2008, 23, 36-42. (Pubitemid 350294868)
Shelton RC, Osuntokun O, Heinloth AN, et al. - Therapeutic options for treatment-resistant depression. CNS Drugs, 2010, 24, 131-161.
Pitchot W, Ansseau M. - Clinical case of the month. Major depression in a diabetic patient. Rev Med Liège, 1995, 50, 451-452.
Fava M. - Augmentation and combination strategies for complicated depression. J Clin Psychiatry, 2009, 70, e40.
Papakostas GI. - Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry, 2009, 70, 16-25.
Ruhé HG, Huyser J, Swinkels JA, et al. - Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry, 2006, 67, 1836-1855. (Pubitemid 46055194)
Papakostas GI, Fava M, Thase ME. - Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry, 2008, 63, 699-704. (Pubitemid 351329277)
Guzzetta F, Tondo L, Centorrino F, et al. - Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry, 2007, 68, 380-383. (Pubitemid 46506801)
Bauer M, Whybrow PC. - Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry, 2001, 2, 57-67.
Pitchot W, Scantamburlo G, Ansseau M. - Dopamine and depression : the forgotten neurotransmitter. Rev Med Liège, 2008, 63, 378-384.
Lattanzi L, Dell'Osso L, Cassano P, et al. - Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord, 2002, 5, 307-314.
Nelson JC, Papakostas GI. - Atypical antipsychotic augmentation in major depressive disorder : a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry, 2009, 166, 980-991.
Berman RM, Fava M, Thase ME, et al. - Aripiprazole augmentation in major depressive disorder : a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr, 2009, 14, 197-206.
Nelson JC, Thase ME, Trivedi MH, et al. - Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry, 2009, 11, 344-352.
Nelson JC, Mankoski R, Baker RA, et al. - Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord, 2010, 120, 133-140.
Nelson JC, Pikalov A, Berman RM. - Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat, 2008, 4, 937-948.
Weisler R, Joyce M, McGill L, et al. - Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr, 2009, 14, 299-313.
McIntyre RS, Muzina DJ, Adams A, et al. - Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother, 2009, 10, 3061-3075.
El-Khalili N, Joyce M, Atkinson S, et al. - Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol, 2010, 23, 1-16.
Trivedi MH, Thase ME, Osuntokun O, et al. - An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry, 2009, 70, 387-396.
Corya SA, Andersen SW, Detke HC, et al. - Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination : a 76-week open-label study. J Clin Psychiatry, 2003, 64, 1349-56.
Keitner GI, Garlow SJ, Ryan CE, et al. - A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res, 2009, 43, 205-214.
Alexopoulos GS, Canuso CM, Gharabawi GM, et al. - Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry, 2008, 16, 21-30.
Freeman MP. - Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry, 2009, 70, 7-11.
Fava M, Mischoulon D. - Folate in depression : efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry, 2009, 70, 12-17.
Vigo DV, Baldessarini RJ. - Anticonvulsants in the treatment of major depressive disorder : an overview. Harv Rev Psychiatry, 2009, 17, 231-241.
Blier P, Ward HE, Tremblay P, et al. - Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry, 2010, 167, 281-288.
McGrath PJ, Stewart JW, Fava M, et al. - Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry, 2006, 163, 531-4151.
López-Muñoz F, Alamo C, Rubio G, et al. - Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. Pharmacopsychiatry, 2007, 40, 14-19. (Pubitemid 46568355)
Parikh SV, Segal ZV, Grigoriadis S, et al. - Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord, 2009, 117, 15-25.
Thase ME, Friedman ES, Biggs MM, et al. - Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments : a STAR*D report. Am J Psychiatry, 2007, 164, 739-752.
